A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Key facts
- Who runs it
- BioNTech SE
- Where
- Athens, Austin, Baltimore, Birmingham, Bristol, Brownsville, Canoga Park, Chesterfield, Chicago, Cincinnati, Clearwater, Columbus, Dallas, Doral, Durham, Fort Lauderdale, Fort Worth, Fullerton, Grand Island, Greenacres City, Hialeah, Hickory, Honolulu, Houston, Idaho Falls, Jacksonville, Kansas City, Knoxville, Lake Forest, Layton, Little Rock, Long Beach, Los Alamitos, Medford, Memphis, Meridian, Mesquite, Miami, Miami Lakes, Mobile, Monroe, Morton, Myrtle Beach, Newport News, Norfolk, North Las Vegas, Oklahoma City, Omaha, Orlando, Palmetto Bay, Papillion, Pembroke Pines, Phoenix, Plano, Raleigh, Rochester, Rocky Mount, Salt Lake City, San Antonio, San Diego, Sandy Springs, Scottsdale, Silver Spring, Sioux City, Southfield, St Louis, Sterling Heights, Stockbridge, Tampa, Tempe, Tomball, Valley Village, Vista, Walnut Creek, Warren Township, West Jordan, Wichita, Wilmington, and Winston-Salem, United StatesSee the 105 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 8,795 people enrolled
- Started
- 20 Dec 2023
- Ended
- 26 Nov 2024
- Type of study
- Interventional, 8 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Influenza and COVID-19 Combination A
- Licensed influenza vaccine
- COVID-19 Vaccine
- Influenza and COVID-19 Combination B
- Placebo
- Investigational influenza vaccine
- Record updated
- 4 December 2025
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants 18 through 64 years of age (or the minimum age of consent in accordance with local regulations) at Visit 1
- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
Who cannot take part
- Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza
- Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (175 days) before study intervention administration; Please refer to the study contact for further eligibility details
Where in United States
- North Alabama Research CenterAthens, United States
- Benchmark ResearchAustin, United States
- Orion Clinical ResearchAustin, United States
- Tekton Research, LLC.Austin, United States
- PharmaronBaltimore, United States
- Accel Research Sites - Birmingham Clinical Research UnitBirmingham, United States
- Internal Medicine and Pediatric Associates of BristolBristol, United States
- Headlands Horizons, LLC dba Headlands Research-BrownsvilleBrownsville, United States
- Hope Clinical Research, Inc.Canoga Park, United States
- Clinical Research ProfessionalsChesterfield, United States
- Great Lakes Clinical Trials - RavenswoodChicago, United States
- Synexus Clinical Research US, IncChicago, United States
- CTI Clinical Research CenterCincinnati, United States
- Synexus Clinical Research US IncCincinnati, United States
- Velocity Clinical Research, Cincinnati, Mt. AuburnCincinnati, United States
- Tampa Bay Medical ResearchClearwater, United States
- Centricity Research Columbus Georgia MultispecialtyColumbus, United States
- DFW Clinical ResearchDallas, United States
- Universal Axon Clinical Research LLCDoral, United States
- Duke Vaccine and Trials UnitDurham, United States
- Proactive Clinical Research,LLCFort Lauderdale, United States
- Benchmark ResearchFort Worth, United States
- Texas Health Family CareFort Worth, United States
- Ascada Health PC dba Ascada ResearchFullerton, United States
- Velocity Clinical Research - Grand IslandGrand Island, United States
- Finlay Medical ResearchGreenacres City, United States
- Best Quality Research, IncHialeah, United States
- Indago Research & Health Center, IncHialeah, United States
- Accellacare - HickoryHickory, United States
- East-West Medical Research InstituteHonolulu, United States
- Santa Clara Family ClinicHouston, United States
- Clinical Research PrimeIdaho Falls, United States
- Clinical Neuroscience Solutions, Inc. dba CNS HealthcareJacksonville, United States
- Alliance for Multispecialty Research, LLCKansas City, United States
- Alliance for Multispecialty Research, LLCKnoxville, United States
- New Phase Research And DevelopmentKnoxville, United States
- Orange County Research CenterLake Forest, United States
- AMR ClinicalLayton, United States
- Baptist Health Center for Clinical ResearchLittle Rock, United States
- Ark Clinical ResearchLong Beach, United States
- Collaborative Neuroscience Research, LLCLos Alamitos, United States
- Velocity Clinical Research, MedfordMedford, United States
- Clinical Neuroscience Solutions, Inc.Memphis, United States
- Solaris Clinical ResearchMeridian, United States
- Velocity Clinical Research, BoiseMeridian, United States
- SMS Clinical ResearchMesquite, United States
- Clinical Site Partners LLC, dba Flourish ResearchMiami, United States
- Entrust Clinical ResearchMiami, United States
- Gerardo Polanco, MDMiami, United States
- Miami Clinical ResearchMiami, United States
- Miami Dade Medical Research Institute, LLCMiami, United States
- Research Institute of South FloridaMiami, United States
- Angels Clinical Research InstituteMiami Lakes, United States
- Palm Springs Community Health CenterMiami Lakes, United States
- AMR ClinicalMobile, United States
- Monroe Biomedical ResearchMonroe, United States
- Koch Family MedicineMorton, United States
- Trial Management AssociatesMyrtle Beach, United States
- Trial Management Associates, LLCMyrtle Beach, United States
- Health Research of Hampton Roads, Inc.Newport News, United States
- AMR ClinicalNorfolk, United States
- Las Vegas Clinical TrialsNorth Las Vegas, United States
- Lynn Health Science InstituteOklahoma City, United States
- Quality Clinical ResearchOmaha, United States
- Velocity Clinical Research - OmahaOmaha, United States
- Clinical Neuroscience Solutions, Inc.Orlando, United States
- Innovation Medical Research CenterPalmetto Bay, United States
- McGill Family PracticePapillion, United States
- DBC Research USAPembroke Pines, United States
- Foothills Research Center Cct ResearchPhoenix, United States
- Hope Research InstitutePhoenix, United States
- ACRC Trials (Administrative Location)Plano, United States
- ACRC TRIALS / North Texas Family MedicinePlano, United States
- Aim Trials, LLCPlano, United States
- M3 Wake Research, Inc.Raleigh, United States
- Rochester Clinical Research, LLCRochester, United States
- Accellacare - Rocky MountRocky Mount, United States
- J. Lewis Research, Inc. / Foothill Family Clinic SouthSalt Lake City, United States
- Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, United States
- IMA Clinical Research San AntonioSan Antonio, United States
- Acclaim Clinical ResearchSan Diego, United States
- Artemis Institute for Clinical ResearchSan Diego, United States
- AGILE Clinical Research Trials, LLCSandy Springs, United States
- Scottsdale Clinical TrialsScottsdale, United States
- Jadestone Clinical ResearchSilver Spring, United States
- Velocity Clinical Research - Sioux CitySioux City, United States
- Headlands Research - DetroitSouthfield, United States
- Saint Louis University Center for Vaccine DevelopmentSt Louis, United States
- Sundance Clinical ResearchSt Louis, United States
- Revival Research Institute, LLCSterling Heights, United States
- Clinical Research AtlantaStockbridge, United States
- Angels Clinical Research InstituteTampa, United States
- Alliance for Multispecialty Research, LLCTempe, United States
- DM Clinical Research - Martin Diagnostic ClinicTomball, United States
- Northwest Houston Heart CenterTomball, United States
- Bayview Research Group, LLCValley Village, United States
- Synexus Clinical Research US, Inc.Vista, United States
- Diablo Clinical Research, Inc.Walnut Creek, United States
- IMA Clinical Research WarrenWarren Township, United States
- Velocity Clinical Research, Salt Lake CityWest Jordan, United States
- AMR ClinicalWichita, United States
- Accellacare - WilmingtonWilmington, United States
- Trial Management Associates - Wilmington - Floral ParkwayWilmington, United States
- Trial Management Associates, LLCWilmington, United States
- Accellacare - Winston-SalemWinston-Salem, United States
About the trial
What the trial wants to find out
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and caregivers in terms of simple and easy care. Around 8550 participants will be assigned into 1 of 8 vaccination groups (Group A, B, C, D, E, F, G or H) by chance.
Read full original descriptionShow less
Cohort 1: Approximately 450 participants will be assigned by chance to one of the following:
* Group A:Influenza and COVID-19 combination A vaccine, given at the same time in one arm and placebo (an injection consisting of just salt water and no medicines in it) in the opposite arm. * Group B: COVID-19 vaccine, given at the same time to one arm and licensed influenza vaccine in the opposite arm.
Cohort 2: Approximately 4500 participants will be assigned by chance to one of the following:
* Group C: Influenza and COVID-19 combination B vaccine, given at the same time in one arm and placebo in the opposite arm. * Group D: COVID-19 vaccine, given at the same time in one arm and licenced influenza vaccine in the opposite arm.
Cohort 3: Approximately 3600 participants will be assigned by chance to one of the following:
* Group E: Influenza and COVID-19 combination B vaccine. * Group F: COVID-19 vaccine. * Group G: Licenced influenza vaccine. * Group H: Investigational influenza vaccine.
All participants in cohort 1 and cohort 2 will receive 2 injections and participants in cohort 3 will receive 1 injection as per their assigned study group at Visit 1. The participants will be followed for about 6 months. During this time, researchers will assess safety and the body's reaction to the vaccination over approximately 6 months. This will help understand if the study medicine is safe.
The 8 groups in the trial
- Cohort 1 Arm A: Influenza and COVID-19 Combination A and PlaceboTreatment being tested
Cohort 1 Arm A: Influenza and COVID-19 combination A vaccine and Placebo
Treatment: Influenza and COVID-19 Combination A and Placebo
- Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration groupExisting treatment, for comparison
Treatment: Licensed influenza vaccine and COVID-19 Vaccine
- Cohort 2 Arm C:Influenza and COVID-19 Combination B and PlaceboTreatment being tested
Cohort 2 Arm C: Influenza and COVID-19 Combination B vaccine and Placebo
Treatment: Influenza and COVID-19 Combination B and Placebo
- Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration groupExisting treatment, for comparison
Treatment: Licensed influenza vaccine and COVID-19 Vaccine
- Cohort 3 Arm E:Influenza and COVID-19 Combination BTreatment being tested
Treatment: Influenza and COVID-19 Combination B
- Cohort 3 Arm F: COVID-19 vaccineExisting treatment, for comparison
Treatment: COVID-19 Vaccine
- Cohort 3 Arm G: Licensed influenza vaccineExisting treatment, for comparison
Treatment: Licensed influenza vaccine
- Cohort 3 Arm H: Investigational influenza vaccineExisting treatment, for comparison
Treatment: Investigational influenza vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS
- Publications
- Record updated
- 4 December 2025